

**Wentao Zhang**

Senior Director
Foster City
zwt68@yahoo.com

Wentao Zhang, Ph.D., is Senior Director of New Lead Discovery at Exelixis in South San Francisco, managing key drug discovery platform and functions that include compound library management, assay development and high-throughput screen efforts, lead optimization, in vitro ADME operations and HERG safety pharmacology. Dr. Zhang has worked extensively in targeted drug discovery covering kinases, GPCR's and nuclear hormone receptors using a wide spectrum of enabling technologies. The drug discovery technology platform that Dr. Zhang helped to establish has generated and progressed over 15 compounds from discovery to clinical development, including candidates in phase 2 and 3 clinical trials. He has been at Exelixis since 2001. Before that, Dr. Zhang was a Staff Scientist at Genelabs Technologies from 1999 to 2001 responsible for biochemical and biophysical assays in the therapeutic areas of oncology and infectious diseases. In 1997-1999, Dr. Zhang was a postdoctoral fellow at University of California-Berkeley in the division of Biochemistry and Molecular Biology. He obtained his Ph.D. in Biophysical Chemistry from University of Wisconsin-Madison, M.S. from Emory University and B.Sc. from Peking University. Dr. Zhang has published extensively in peer-reviewed scientific journals and holds multiple patents. He has been actively involved in various professional services and organizations, including serving on the NIH study section on assay development. Dr. Zhang has extensive management experience and has played key leadership roles in the biopharmaceutical industry.

张文涛，博士。1991 年于北京大学获化学学士，同年赴美留学。1993 年在爱默里大学获化学硕士，1996 年在威斯康星大学获生物物理化学博士学位，1997-99 年在加大伯克利分校做博士后研究。在此阶段，张博士的研究方向主要涉及蛋白质与核酸相互作用机理，蛋白质的稳定性，脱氧核糖核酸拓扑酶和重组酶的机理。1999 年加入位于旧金山湾区的 Genelabs 生物技术公司，主持其生化研究和抗传染病的药物研发，并负责 DARPA 科研项目的生化测试。2001 年加盟 Exelixis 公司，历任科学家，高级科学家，研发副总监和研发总监。自 2009 年张博士任新药研发高级总监，主管新药化学库，分子活性测试，高通量和超高通量药物筛选，药物分子优化，药物分子的吸收、分布、代谢和排泄，以及药物分子的安全与毒性测试。张博士领导设计了新药筛选，优化和研发的技术平台，并推动十几个抗癌新药进入临床试验，其中包括二，三期临床药物。张博士有多年的高层管理经验，包括领导超过 35 人的技术团队和跨领域人才。科研上，张博士领导多个课题小组，主要从事蛋白激酶，G 蛋白偶联受体，和核激素受体的靶向药物研发。张博士发表了十几篇科学论文并拥有多项专利，是美国卫生部国家卫生研究院特邀项目评审专家。